I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 6.61 USD -0.15% Market Closed
Market Cap: 426.8m USD

During the last 3 months Immuneering Corp insiders have not bought any shares, and have not sold any shares. The stock price has increased by 5% over this period (open performance analysis).

The last transaction was made on Oct 3, 2025 by Feinberg Peter , who bought 50k USD worth of IMRX shares.

Last Transactions:
Feinberg Peter
$+50k
Bookman Michael
$+7k
Neufeld Leah R
$+5.1k
Morales Mallory
$+1.9k
Feinberg Peter
$+52.7k
Feinberg Peter
$+35.9k
Hausman Diana
$+9k
Neufeld Leah R
$+2.5k
Zeskind Benjamin J.
$+24.8k
Zeskind Benjamin J.
$+10.1k
Schall Thomas J.
$+34.8k
Hall Brett Matthew
$+14.6k
Brakewood Harold Eugene
$+4.8k
Hall Brett Matthew
$+20k
Feinberg Peter
$+63.2k
Zeskind Benjamin J.
$+50.1k
Schall Thomas J.
$+89.3k
Cormorant Asset Management, Lp
$-307
Morales Mallory
$+1k
Schall Thomas J.
$+7.4k
Feinberg Peter
$+63.7k
Brakewood Harold Eugene
$+10k
Morales Mallory
$+3k
Neufeld Leah R
$+11k
Hall Brett Matthew
$+20k
Feinberg Peter
$+64k
Zeskind Benjamin J.
$+55.3k
Berman Ann E
$+123.4k
Feinberg Peter
$+103.9k
Cormorant Asset Management, Lp
$-856.4k
Cormorant Asset Management, Lp
$-1.1m
Hall Brett Matthew
$+10k
View All Transactions

During the last 3 months Immuneering Corp insiders have not bought any shares, and have not sold any shares. The stock price has increased by 5% over this period (open performance analysis).

The last transaction was made on Oct 3, 2025 by Feinberg Peter , who bought 50k USD worth of IMRX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
4
152.6k USD
6-9
months
7
323.2k USD
9-12
months
No Insider Transactions
0
0 USD

Immuneering Corp
Insider Trading Chart

Immuneering Corp
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Immuneering Corp
Last Insider Transactions

Global
Insiders Monitor

Immuneering Corp
Glance View

Market Cap
419.6m USD
Industry
Biotechnology

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

IMRX Intrinsic Value
Not Available
I

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top